ACA
Acorn Capital Advisors Portfolio holdings
AUM
$153M
This Quarter Return
-4.13%
1 Year Return
–
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$186M
AUM Growth
–
Cap. Flow
+$186M
Cap. Flow
% of AUM
100%
Top 10 Holdings %
Top 10 Hldgs %
79.24%
Holding
21
New
21
Increased
–
Reduced
–
Closed
–
Top Buys
| 1 |
CG Oncology
CGON
|
$32.5M |
| 2 |
Y-mAbs Therapeutics
YMAB
|
$22.4M |
| 3 |
Candel Therapeutics
CADL
|
$16.8M |
| 4 |
UroGen Pharma
URGN
|
$16.1M |
| 5 |
Puma Biotechnology
PBYI
|
$12M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
CG Oncology
CGON
$2.04B
| $32.5M | 17.46% | +1,131,501 | New | +$32.5M |
|
|
2
Y-mAbs Therapeutics
YMAB
$388M
| $22.4M | 12.06% | +2,861,825 | New | +$22.4M |
|
|
3
Candel Therapeutics
CADL
$318M
| $16.8M | 9.06% | +1,939,644 | New | +$16.8M |
|
|
4
UroGen Pharma
URGN
$900M
| $16.1M | 8.69% | +1,516,303 | New | +$16.1M |
|
|
5
Puma Biotechnology
PBYI
$254M
| $12M | 6.47% | +3,940,052 | New | +$12M |
|
|
BCAX
6
Bicara Therapeutics Inc. Common Stock
BCAX
$651M
| $11.2M | 6.03% | +643,381 | New | +$11.2M |
|
7
Terns Pharmaceuticals
TERN
$609M
| $10.9M | 5.88% | +1,971,264 | New | +$10.9M |
|
|
OKUR
8
OnKure Therapeutics, Inc. Class A Common Stock
OKUR
$37.2M
| $10.2M | 5.51% | +1,439,674 | New | +$10.2M |
|
9
Trevi Therapeutics
TRVI
$883M
| $8.24M | 4.44% | +2,001,048 | New | +$8.24M |
|
10
Protara Therapeutics
TARA
$120M
| $6.76M | 3.64% | +1,279,800 | New | +$6.76M |
|
|
CYBN
11
Cybin
CYBN
$176M
| $6.48M | 3.49% | +734,393 | New | +$6.48M |
|
12
Cardiff Oncology
CRDF
$140M
| $6.26M | 3.37% | +1,442,308 | New | +$6.26M |
|
13
X4 Pharmaceuticals
XFOR
$84.2M
| $5.36M | 2.89% | +7,310,650 | New | +$5.36M |
|
14
Mural Oncology
MURA
$35.7M
| $4.14M | 2.23% | +1,286,079 | New | +$4.14M |
|
|
WHWK
15
Whitehawk Therapeutics, Inc. Common Stock
WHWK
$84.8M
| $3.62M | 1.95% | +1,147,052 | New | +$3.62M |
|
|
OPTN
16
DELISTED
OptiNose
OPTN
| $2.82M | 1.52% | +422,813 | New | +$2.82M |
|
17
Q32 Bio
QTTB
$20.9M
| $2.76M | 1.49% | +803,425 | New | +$2.76M |
|
18
Acrivon Therapeutics
ACRV
$42.2M
| $2.44M | 1.31% | +405,237 | New | +$2.44M |
|
19
BioAtla
BCAB
$26.7M
| $2.38M | 1.28% | +4,032,046 | New | +$2.38M |
|
20
VYNE Therapeutics
VYNE
$8.16M
| $1.53M | 0.82% | +456,970 | New | +$1.53M |
|
21
Verastem
VSTM
$569M
| $779K | 0.42% | +779,498 | New | +$779K |
|